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Abstract
Background: Fibrosis is a common side effect after treatment with ionizing radiation. Several
methods to ameliorate debilitating fibrosis have been employed but without consistent results. The
goal of this pilot study is to determine if Pirfenidone, a novel regulator of cytokine gene expression,
has the potential to ameliorate established radiation-induced fibrosis.
Methods: Open label, prospective pilot study of 800 mg three times/day, orally administered
Pirfenidone was administered to enrolled patients who were had completed radiation therapy and
who had established radiation-induced fibrosis. Range of motion (ROM) was assessed using
standard measures, and subjective measures of pain, fatigue, disability and global health were
measured every three months.
Results: Seven patients were enrolled of whom 3 had ROM assessments of 1 site and 2 had ROM
assessments of 2 sites. Of these assessments, 6 revealed increased ROM during drug intervention
while 1 revealed a decreased ROM. There was an overall improvement in the mental composite
score of the SF36 while physical composite score was decreased and the vitality score was
unchanged. Two patients were removed from the study because of syncopal episodes.
Conclusion:  Several patients experienced improved function of at least 25% and reported
subjective improvement. Pirfenidone may benefit patients with radiation-induced fibrosis and is
worthy of a larger well controlled trial.
Background
Fibrosis is a major cause of morbidity after treatment with
ionizing radiation [1-3]. Manifestations of fibrosis are
usually tissue specific with effects ranging from limitation
of mobility to poor wound healing and neuropathy. For
example, irradiation of the brain induces gliosis whereas
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in the lung, radiation results in an acute inflammatory
response often followed by chronic fibrosis manifested as
restrictive lung disease and decreased diffusion capacity.
Radiation-induced fibrosis of the skin and connective tis-
sue can lead to contractures, ulcerations and neuropathy
resulting in decreased mobility and difficulty swallowing
and speaking [4]. As a result, fibrosis is a dose-limiting
toxicity related to radiotherapy.
While the mechanism underlying chronic fibrosis is not
fully known, vascular damage and the release of inflam-
matory cytokines and other factors such as platelet
derived growth factor (PDGF), endothelial growth factor
(EGF) and fibroblast growth factor (FGF) stimulate
fibroblast activation which seems to initiate a pro-fibrotic
cascade of events [5-10]. Decreasing the radiation dose to
sensitive structures is the mainstay of prevention of fibro-
sis. Other approaches moderate the developing fibrotic
process post-irradiation including administration of
hyperbaric oxygen, and the use of drugs such as pentoxi-
fylline [11] and Vitamin E [12]. Recent studies report the
potential benefit of combined therapy using Vitamin E
and pentoxifylline after radiotherapy to reverse fibrosis
[13,14] but larger trials are needed to confirm these
results.
Pirfenidone (5-methyl-N-phenyl-2-(1H)-pyridone) is a
novel, small, non-peptide, selective regulator of gene
expression induced by molecular signals from cytokines
such as transforming growth factor-β1 (TGF-β1), PDGF,
β-FGF, EGF, tumor necrosis factor-α(TNF-α) and related
families. Pirfenidone has been shown in several animal
models as well as human in vitro studies to alter cytokine
signaling and reduce or eliminate pulmonary inflamma-
tion and fibrosis. Pirfenidone is currently being evaluated
in phase 2 and 3 clinical trials for the treatment of idio-
pathic pulmonary fibrosis [15] and trials are ongoing for
patients with scleroderma, sclerosing peritonitis, prolifer-
ative vitreoretinopathy, myelofibrosis with myeloid meta-
plasia, renal focal segmental glomerulosclerosis and
patients with pulmonary fibrosis associated with Her-
mansky-Pudlak Syndrome (a list of trials involving Pirfe-
nidone is available at http://www.clinicaltrials.gov). No
studies have been conducted, however, looking at the
effectiveness of Pirfenidone in ameliorating or treating
established fibrosis resulting from radiation therapy. We
initiated this pilot study to examine whether Pirfenidone,
administered in a daily oral dose, can decrease chronic
radiation-induced fibrosis and lead to improvements in
mobility and function.
Methods
The patients enrolled in this IRB approved study from our
follow-up clinic had undergone regional radiation treat-
ments and had developed fibrosis of the neck, back or
extremities that caused at least moderately severe loss of
range of motion (> 25% normal range of motion),
strength, swallowing or significant edema. Patients had
completed radiation therapy at least six months prior to
enrollment to ensure that observations were not con-
founded by acute radiation effects. The patients were
given a total of 2400 mg Pirfenidone orally each day
divided into three 800 mg doses which is the same dose
used in other trials studying the efficacy of Pirfenidone
[16,17]. The patients were seen in our radiation oncology
follow-up clinic as well as in the Rehabilitation Medicine
Department every three months while receiving Pirfeni-
done. Prior to initiating therapy and at each subsequent
visit, the patients were questioned about subjective
changes in fibrosis-related symptoms and potential
adverse effects related to the medication. Compliance
with therapy was determined by patient self-reporting as
well as pill counts at each visit. Patients were encouraged
to call the treating physician immediately if they devel-
oped any new symptoms or problems.
Enrolled patients were evaluated at baseline and at three
monthly intervals by an experienced and trained rehabili-
tation staff who performed active and passive range of
motion assessments, muscle testing and administered
questionnaires as per the protocol. Cervical range of
motion, using an inclinometer, was measured in 4 planes
of motion including flexion, extension, right and left rota-
tion and right and left lateral flexion. Ten upper and lower
extremity ranges of motion were measured including
extension, flexion, adduction, abduction, internal rota-
tion, external rotation, extension and flexion at the elbow
or knee, and extension and flexion at the wrist or ankle.
For each body site, the maximum possible ROM was cal-
culated by summing the degrees of freedom in all planes
of motion. The patient's total ROM was determined by
summing the actual measured degrees of ROM in each
plane and this was compared to the maximum possible
ROM. Finally, the patients completed five written surveys
at each visit: the Fatigue Severity Scale (FSS) [18,19], the
Human Activity Profile (HAP) [20], a measure of activity
level, a Dyspnea scale [21], the Pain Disability Index
(PDI) [22,23], and the SF-36 v.2 (Medical Outcomes
Trust, Inc. Boston, MA) global health survey [24]. All of
these are commonly employed, validated tools that relia-
bly measure various patient reported factors related to
health related quality of life and function. Patients were
enrolled six months or longer after the completion of radi-
otherapy to eliminate potentially confounding acute
inflammatory changes and were evaluated every three
months for a total of two years. All patient data were col-
lected and analyzed by the Rehabilitation Medicine
Department.Radiation Oncology 2007, 2:19 http://www.ro-journal.com/content/2/1/19
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Results
Seven patients were enrolled in the study, however two
were removed from the study after experiencing syncopal
episodes during treatment and no further assessments of
these patients were made. Of the five patients who
remained in the study, all were treated for the entire two
year period and their characteristics are noted in Table 1.
The patients ranged in age from 53 to 60 years old and all
were men. Four of the patients had been treated for head
and neck cancer and one had been treated for Hodgkin's
Disease. At the time of enrollment, 4 patients complained
of limited cervical mobility of whom 2 also complained of
limited UE mobility. One patient complained only of lim-
ited LE mobility. All of the patients reported a subjective
improvement in their symptoms over time. This included
a perceived improvement in their mobility and range of
motion and subsequent improvement in activities of daily
living. Analysis of the SF36 survey revealed a somewhat
mixed picture. One patient demonstrated an improve-
ment in the Vitality score, a subset of questions that meas-
ures energy and fatigue, while three remained unchanged
and one had a decreased score. Two of the patients exhib-
ited an improvement in the Mental Competency Compos-
ite Score (MCS), a component of the SF36 that reports a
patient's impression of their overall health, however the
other three had no change. In two cases there was a slight
improvement in the Physical Competency Composite
Score (PCS), a component of the SF36 that reports the
patient's physical abilities and impairments, a significant
decrease in one case and two patients reported no change.
Taken as a group, there was an overall trend towards
improvement in the MCS score of the SF36 which corre-
sponds with the patient's subjective reports of improve-
ment. There was, however, a slight overall worsening of
the PCS and Vitality scores during the drug therapy (Fig-
ure 1). There were no significant changes in the Fatigue
Severity Scale (FSS), the Human Activity Profile (HAP),
the Dyspnea scale, or the Pain Disability Index (data not
shown).
Like the SF36 MCS, the quantitative ROM measurements
revealed a trend towards improvement. As previously
described, the patient's total cervical spine ROM was
measured in the four patients previously treated to the
head and neck region (Figure 2). Of these, three had meas-
urable improvement of 24, 31 and 73% while one had a
decline in total ROM of 8%. Two patients had upper
extremity measurements and both had an improvement
of over 100 degrees total ROM translating to an improve-
ment of 10 and 15% (Figure 2). The one patient who had
lower extremity measurements showed an improvement
in total ROM of nearly 50 degrees, or 11% above baseline
(Figure 2).
Two patients discontinued the medication because of pos-
sible adverse events. Both patients had self-reported syn-
copal episodes while taking Pirfenidone and both
underwent thorough evaluations by their primary care
physicians and cardiologists but no definite etiology was
found. Neither patient had suffered from a seizure, myo-
cardial infarct, cerebrovascular accident or other vascular
event. In both cases the patients recovered fully within
minutes of the event and had no subsequent events that
were reported to us. In the interest of patient safety, how-
ever, the events were reported to the manufacturer of the
drug, and the patients were removed from the study.
Discussion
This report documents the findings from a pilot study
involving a small number of subjects treated with Pirfeni-
done, a novel regulator of cytokine gene expression,
administered a minimum of six months after the comple-
tion of radiation therapy. Improvement in ROM was doc-
umented for six of the seven patients. In this study,
patients exhibited a slight improvement in overall func-
tion as a result of treatment with Pirfenidone during the
two year follow-up period. ROM was modestly but con-
sistently improved over a two year period, and loss of
range of motion over time is not uncommon in people of
this age group. Additionally, the natural history of radia-
tion induced fibrosis is that of slowly increasing loss of
range of motion, with stiffness which may plateau but
does not spontaneously improve. This is especially true
for those with well established fibrosis and persistent
functional loss. For all patients in this study, ROM
improved and in several this was associated with func-
tional improvement.
Fibrosis is a significant long-term side effect of treatment
with ionizing radiation [1,2] which can limit mobility and
contribute to poor wound healing and neuropathy [3].
Because of its frequency and potential severity, fibrosis
can be a dose-limiting toxicity. Although the manifesta-
tions of fibrosis are tissue-specific, the underlying mecha-
nism generally involves vascular damage and cytokine
release [5-9]. Increased vascular permeability results in the
influx of inflammatory cells and the subsequent release of
factors such as TNF-α, TGF-β, and interleukins. These
stimulate fibroblasts to increase production of extracellu-
lar matrix proteins and to secrete chemotactic signals that
promote additional fibroblast recruitment resulting in a
robust pro-fibrotic stimulatory cascade [25,26].
Several techniques to reduce fibrosis have been used with
varying degrees of success but avoidance of irradiation
remains the mainstay of prevention. Careful treatment
planning allows for the irradiation of the smallest possi-
ble field at the lowest effective dose, however significant
fibrosis is often inevitable. Several pharmaceuticals andRadiation Oncology 2007, 2:19 http://www.ro-journal.com/content/2/1/19
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the administration of hyperbaric oxygen have attempted
to address the problem by targeting tissue hypoxia. How-
ever, the potential for the promotion of regrowth of resid-
ual malignant cells and the potentially toxic effects of
oxygen itself have precluded the widespread use of hyper-
baric oxygen, and most pharmaceutical agents have been
found to be ineffective.
Administration of the drug pentoxifylline during or after
radiation treatment is thought to improve microcircula-
tion and oxygenation [11] and may prevent or even
reverse the development of fibrosis. A recent review of the
literature, however, found little evidence that pentoxifyl-
line alone reduces the acute side effects of radiotherapy
[27]. Many studies of pentoxifylline include the addition
of Vitamin E analogues, but studies investigating the com-
bination treatment have also had varying degrees of suc-
cess [12]. An animal study compared the effect of
pentoxifylline alone to the combination of pentoxifylline
and α-tocopherol following exposure to a single 160 Gy
radiation dose [28]. The authors reported a significant
reduction in the formation of fibrosis with combination
therapy but no benefit from pentoxifylline alone. A recent
study found that four of 23 patients undergoing pelvic
irradiation demonstrated significant clinical benefit from
combined therapy with pentoxifylline and α-tocopherol,
but none reported an improvement in symptoms or func-
tion on patient self-assessment questionnaires [13]. A
study of 24 women who had undergone radiation therapy
Total Range of Motion Measurements Figure 2
Total Range of Motion Measurements. The total ROM 
(sum for all planes of motion) was calculated for each patient 
for the cervical spine, upper extremity and lower extremity. 
Maximum possible total ROM is represented at the top of 
each graph by a dotted line. Each patient is represented indi-
vidually. For the four patients with cervical ROM measure-
ments, Patient 1 showed an improvement of 73%, Patient 2 
improved by 31%, and Patient 3 improved by 24%. Patient 4 
had a decline in function of 8%. Both patients with upper 
extremity ROM measurements show an improvement of 
over 100 degrees of ROM during the drug therapy with 
Patient 1 showing a 15% improvement and Patient 2 improv-
ing by 10%. For the single patient with lower extremity ROM 
measurements, there is a total improvement of approxi-
mately 50 degrees of ROM during the drug therapy which is 
11% above baseline.
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Patient 1
Patient 2
Table 1: Patient Characteristics
Age Gender Tumor Location Radiation Dose (Gy) Time from Completion of Radiation (Months) ROM Impairment at Baseline Duration of Pirfenidone Treatment 
(Months)
60 M Head and Neck 63 46.0 Decreased Cervical ROM 25.0
60 M Head and Neck 72 32.1 Decreased Cervical ROM 24.6
54 M Hodgkin's 45 – Pelvis 36 – PA 198.8 Decreased LE ROM and Strength 24.0
59 M Head and Neck 70.2 53.7 Decreased UE and Cervical ROM 23.3
56 M Head and Neck 60 69.1 Decreased UE and Cervical ROM 22.4
53 M Hodgkin's 54 – Mantle 36 – PA 276.5 Decreased Cervical ROM 6.3 (removed from study)
60 M Head and Neck 70 23.4 Decreased Cervical ROM 3.0 (removed from study)
Average SF36 Component Scores Figure 1
Average SF36 Component Scores. The average score 
for all patients for each component of the SF36 is shown. 
During drug therapy, the vitality component score shows lit-
tle change (-3%), the physical composite score decreases by 
33% while the mental composite score shows an increase of 
17%.
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for breast cancer reported regression of fibrosis after 6
months of treatment with pentoxifylline and vitamin E
[14]. No improvement was observed in patients taking
either medication alone.
While several receptor tyrosine kinase inhibitors have
been shown to block radiation-induced PDGF signaling
resulting in decreased pulmonary fibrosis, no studies have
been conducted examining the prevention of fibrosis at
other sites [29]. Pirfenidone selectively regulates gene
expression signaling from pro-fibrotic cytokines such as
TGF-β1, PDGF, β-FGF, EGF, and TNF-α. In pre-clinical
studies, Pirfenidone altered TGF-β transcription in a
murine model of bleomycin-induced pulmonary fibrosis
[30], IL-6 expression in rat models of acute pulmonary
inflammation [31], and expression of ICAM-1 in cultured
human fibroblasts [32]. Pirfenidone has also been shown
to ameliorate cyclophosphamide and bleomycin-induced
fibrosis in hamsters and mice [33,34], and liver fibrosis
[35] and sclerosing peritonitis in rats [36]. This is the first
study to test the possible usefulness of Pirfenidone in the
treatment of radiation-induced deep tissue fibrosis.
Several metrics used in this study to evaluate the clinical
response to Pirfenidone, such as questionnaires, are
somewhat subjective. Although objective measures, such
as standardized ROM measurements, were employed by
physical therapists, some subjectivity remains because of
the nature of the testing and because patients were not
always assessed by the same therapist making subtle dif-
ferences in patient function more difficult to detect.
In studies reporting on side effects associated with the use
of Pirfenidone, gastrointestinal complaints were common
[15,37], photosensitivity occurred in several patients
[37,38] and in one study a single patient complained of
dizziness [37]. In our cohort, most patients noted a phase-
in period that was associated with fatigue and occasional
nausea. These symptoms were mild and short lived and
did not necessitate a dose adjustment. Nausea was
improved when the medication was taken with food. Two
patients in this trial had what appeared to be syncopal epi-
sodes. Both had significant fibrosis resulting from radia-
tion treatment for head and neck cancer which can cause
compression of the carotid sinus resulting in syncope and
which may have been the underlying cause in these
patients. Although these patients did not have any further
episodes, they were removed from the study and the
events were reported to the drug manufacturer. Syncope as
a result of Pirfenidone treatment has not been reported
elsewhere. No other significant side-effects were reported.
Conclusion
The stabilization of function and fibrosis-related symp-
toms in this set of patients suggests that Pirfenidone may
be effective in ameliorating the disability associated with
radiation-induced fibrosis. Future trials are required to
determine optimal therapeutic dosing, timing interval,
duration of treatment, and to establish efficacy. Ideally,
objective measures should include determination of tis-
sue resilience using imaging technologies. Subjective
measures utilizing a single blinded observer for ROM met-
rics should be of adequate sensitivity to document clinical
meaningful change. Because other treatments are of lim-
ited utility, a larger, well controlled trial is warranted as
Pirfenidone shows promise in ameliorating this debilitat-
ing side-effect of radiation therapy.
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